Table 1.
Intraocular Pressure (IOP) After Repeated (30 µL/eye, BID) VEH, NCX 470, LUM, or BIM Treatments in ET-1-Treated Eyes
| Intraocular Pressure (IOP, mmHg) | ||||||
|---|---|---|---|---|---|---|
| Time After ET-1 First Dose | Week 0 Baseline | Week 2 ET-1 | Week 3 ET-1 + VEH or Test Items | Week 4 ET-1 + VEH or Test Items | Week 5 ET-1 + VEH or Test Items | Week 6 ET-1 + VEH or Test Items |
| VEH | 20.5 ± 0.8 | 23.9 ± 0.4 | 24.0 ± 0.6 | 24.7 ± 0.4 | 24.8 ± 0.3 | 24.8 ± 0.3 |
| NCX 470 | 20.7 ± 0.7 | 22.4 ± 0.9b | 18.7 ± 0.9a,b | 18.4 ± 0.5a,b | 18.1 ± 0.5a,b | 18.1 ± 0.6a,b |
| LUM | 21.5 ± 0.5 | 22.1 ± 0.9 | 20.5 ± 1.3 | 20.6 ± 0.9a | 21.1 ± 0.4a | 20.7 ± 0.7a |
| BIM | 19.5 ± 1.1 | 25.4 ± 0.3a | 23.1 ± 0.8 | 22.8 ± 1.1 | 22.3 ± 0.7a | 21.6 ± 0.5a |
Week 0 refers to baseline IOP (mmHg); week 2 refers to IOP values registered in eyes treated for 2 weeks with ET-1 (twice/week, 200 µL of 250 nM); weeks 3, 4, 5, and 6 refer to IOP values registered in eyes treated with ET-1 + VEH, (n = 7) or test items (NCX 470, n = 7; LUM, n = 4; BIM, n = 6). Data are reported as mean ± SEM, multiple t-test with Welch correction.
a
p < 0.05 versus VEH.
b
p < 0.05 versus LUM or BIM at the same time point.